Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Dec 14, 2010

Premium

Norwegian company iSentio, maker of the web-based sequence analysis software RipSeq, has a new chairman of the board and investors.

Siri Fürst has been named chairman of the board. Fürst has held managerial positions at Hafslund, Hafslund Nycomed, and Nycomed Pharma and served as CEO at DiaGenic. In 2005 she joined Considium Consulting Group. She holds a degree in economics from the Norwegian School of Economics and Business Administration.

Norwegian seed capital fund company Sarsia Seed has become a new investor and will hold two positions on iSentio's board. Sarsia Seed invests in early-phase technology companies within the energy, cleantech, and life science sectors.


Biotech company Nodality has appointed Greg Critchfield to its board of directors. Critchfield recently retired as president of Myriad Genetic Laboratories, where he launched seven diagnostics products. Prior to Myriad, he served as Quest Diagnostics' chief medical and science officer.

He holds a BS in microbiology with a minor in chemistry from Brigham Young University, an MD from the University of Utah, and an MS in biophysical sciences from the University of Minnesota.


The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.